TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02243449

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At least twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
Study: NCT01580436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Annuloplasty
Description: Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
Study: NCT04397185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Locator (BCL) guided partial mastectomy
Description: The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
Study: NCT04084275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: In this training, the amount of nutrients that breastfeeding women should take daily was explained.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fatigue education
Description: In this training, suggestions were made to prevent the negative effects of fatigue

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep education
Description: In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pilates exercises education
Description: In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
Study: NCT01730768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02290990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
Study: NCT01135368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study: NCT00824746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib retreatment
Description: phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
Study: NCT04126759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.3
Description: Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
Study: NCT00809549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgrastim
Description: 10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
Study: NCT04449016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Repeated, brief, and intense exercise bouts separated by active recovery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Repeated, brief, and intense exercise bouts separated by active recovery
Study: NCT04268173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-Based, Client-Centered Prevention Home
Description: Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
Study: NCT03404856

Intervention type: DRUG
Group type: OTHER
Intervention: ORL-1G - D-galactose
Description: Oral ORL-1G - D-galactose
Study: NCT01304407

Intervention type: OTHER
Group type: OTHER
Intervention: Calcium stable isotope
Description: Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
Study: NCT04353700

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga group
Description: During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
Study: NCT01375608

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: 0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
Study: NCT03583827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
Study: NCT00715858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: capsule, 100 mg, b.i.d., 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: capsule, 100 mg, b.i.d., 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin
Description: capsule, 300 mg, od, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin
Description: capsule, 300 mg, od, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matched to rifampin; placebo matched to doxycycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matched to rifampin; placebo matched to doxycycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matched to rifampin; placebo matched to doxycycline
Study: NCT05233345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: online occupational therapy sessions are based on the activity training
Study: NCT01065831

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational interviewing (MINT-TLC)
Description: The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MINT-TLC)
Description: The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
Study: NCT01353911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Four 200 mg capsules orally three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Grazoprevir
Description: Orally once daily in AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Boceprevir
Description: Four capsules orally three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Boceprevir
Description: Four capsules orally three times daily.
Study: NCT02141997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: ABT-122 administered as subcutaneous injection every other week (EOW)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: ABT-122 administered as subcutaneous injection every other week (EOW)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: ABT-122 administered as subcutaneous injection every other week (EOW)
Study: NCT02449174

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Microbiota
Description: Frozen Microbiota will be delivered via enema route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized Microbiota
Description: Lyophilized Microbiota will be delivered orally.
Study: NCT03685084

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AAI101 i.v.
Description: 600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAI101 i.v.
Description: 600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% infusion
Description: Vehicle infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline 0.9% infusion
Description: Vehicle infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin i.v.
Description: piperacillin 3 g i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime i.v.
Description: cefepime 1 g i.v.
Study: NCT01184547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combex
Description: 12 weeks of exercise with a trainer post discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: No exercise training received.
Study: NCT01592344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter - active stimulation
Description: The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 100-250 µsec~* Pulse Rate: 50-100 Hz~* Intensity: 0-30mA Time Settings~* Constant Stim: On~* Total Time: 6 hour

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: StimRouter - Control
Description: The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 200 µsec~* Pulse Rate: 1 Hz~* Intensity: 0 mA Time Settings~* Constant Stim: On~* Total Time: 6 hour
Study: NCT03710655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitox - pure honeybee toxin
Description: Intradermal injection of 0.01 microliters
Study: NCT01353911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Boceprevir
Description: Four capsules orally three times daily.
Study: NCT03710655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of 0.01 microliters
Study: NCT02296385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triple Strength Fish Oil
Description: Triple Strength Fish Oil
Study: NCT02259361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release oral dalfampridine
Description: One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
Study: NCT06093412

Intervention type: PROCEDURE
Intervention: unilateral epidural anesthesia
Description: The patients received unilateral epidural anesthesia

Intervention type: PROCEDURE
Intervention: combined lumbar and epidural anesthesia
Description: The patients received combined lumbar and epidural anesthesia
Study: NCT03536403

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EOS X-rays
Description: EOS X-rays is done with et without a kyphosis induced corset

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-meters walk test
Description: 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
Study: NCT00798109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational therapy
Description: One hour of motivational therapy each weak during 4 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Patients received at least six hour of usual therapy, as in the experimental group
Study: NCT00387478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL or Tree MATA
Description: 4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL or Tree MATA
Description: 4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tree MATA MPL or Tree MATA
Description: 4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo
Study: NCT04663581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Sided Colonoscopy
Description: Starting colonoscopy with the patient in left decubitus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Right Sided Colonoscopy
Description: Starting colonoscopy with the patient in right decubitus
Study: NCT02514837

Intervention type: DEVICE
Intervention: RTM
Description: Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
Study: NCT03759561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intubation with videolaryngoscope vs fiberoptic bronchoscope
Description: Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intubation with videolaryngoscope vs fiberoptic bronchoscope
Description: Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
Study: NCT04397185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wire Localized (WL) partial mastectomy
Description: Standard of care procedure
Study: NCT02542332

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: With Data
Description: The participants received statistical data about lung cancer screening in order to help them answer the questionaire
Study: NCT03302091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: 28 day treatment period
Study: NCT01353911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Boceprevir
Description: Four capsules orally three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.
Study: NCT01277211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENG 120 µg + EE 15 µg intravaginal ring
Description: 13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRSP 3 mg + EE 30 µg
Description: 13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
Study: NCT04098510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Subjects ingest 8x20 mg MitoQ capsules